United States Providers

Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

11/6/2026, 4:29:00 PM

EXECUTIVE SUMMARY

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

Hims & Hers struck a GLP-1 deal with Lilly.
Its stock is rallying..
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

Published originally on MarketWatch Top Stories

🇺🇸 United States

Finance & Markets44m ago

“I haven’t committed to the strategy yet and would appreciate some independent perspectives.”

MarketWatch Top Stories

Finance & Markets54m ago

Daly called Friday's jobs report "good news for American workers," but noted the pressure inflation is exerting on household finances

CNBC Finance

Finance & Markets1h ago

Shares of the online betting platform slid more than 26% on Friday, as analysts worry about regulation and competition.

MarketWatch Top Stories

Finance & Markets1h ago

Also in Weekend Reads: Ideas for generating investment income, new tax brackets, buying a home with cash and advice from the Moneyist.

MarketWatch Top Stories

Multikhabar App

Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!